ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,065.20
-0.08%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36175
0.02%
Bitcoin
66,748.83
2.31%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Calliditas Therapeutics Ab (0A5R)

  7. Calliditas Therapeutics Ab (0A5R) News

0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0A5R
DateTimeSourceHeadlineSymbolCompany
08/18/20233:21AMPR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
08/18/20233:17AMPR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
08/17/202312:29AMPR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
08/15/20233:52AMPR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
08/15/20233:50AMPR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
07/13/20231:20AMPR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
07/13/20231:17AMPR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
06/21/20233:12AMPR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
06/21/20233:10AMPR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
05/30/20239:18AMPR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
05/30/20239:16AMPR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
05/16/202312:17AMPR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/16/202312:14AMPR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/20238:01AMPR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/20238:00AMPR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
04/28/20233:54AMPR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
04/28/20233:51AMPR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
04/26/20239:40PMPR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
04/26/20235:15PMPR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
03/31/202310:24AMPR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
03/31/202310:20AMPR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
03/12/202310:15PMPR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
03/12/202310:06PMPR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
02/23/202312:41AMPR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/23/202312:34AMPR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/02/20232:46AMPR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
02/02/20232:44AMPR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
01/31/20231:22AMPR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
12/30/20222:03AMPR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
12/30/20222:00AMPR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
 Showing the most relevant articles for your search:LSE:0A5R

Your Recent History

NYSE
IPOE.U
Social Capital Hedosophi...
NEO
RDE
Purpose Core Equity Income
UNSW
PASSETH
Passport Finance
COIN
RFOXETH
RedFOX Labs
AMEX
IEUR
MSCI Europe
LSE
DWCU
NYSE
PCPC.WS
Periphas Capital Partner...
COIN
BESTUST
Bitpanda Ecosystem Token
UPBT
TKRW
Threshold Network Token
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved